Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel P Zimmer

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|February 15, 2003
Structural origins of adenine-tract bendingAndrej Barbic, Daniel P Zimmer, Donald M Crothers
FASEB Bioadvances|August 25, 2020
An impaired natriuretic peptide hormone system may play a role in COVID-19 severity in vulnerable populationsMark G Currie, Daniel P Zimmer, Perry V Halushka
Genetics|September 3, 2004
Genome image programs: visualization and interpretation of Escherichia coli microarray experimentsDaniel P Zimmer, Oleg Paliy, Brian Thomas, et al.
Handbook of Experimental Pharmacology|July 6, 2019
Correction to: Soluble Guanylate Cyclase Stimulators and ActivatorsPeter Sandner, Daniel P Zimmer, G Todd Milne, et al.
Handbook of Experimental Pharmacology|January 29, 2019
Soluble Guanylate Cyclase Stimulators and ActivatorsPeter Sandner, Daniel P Zimmer, G Todd Milne, et al.
Methods in Molecular Biology (Clifton, N.J.)|April 25, 2003
Escherichia coli spotted double-strand DNA microarrays: RNA extraction, labeling, hybridization, quality control, and data managementArkady B Khodursky, Jonathan A Bernstein, Brian J Peter, et al.
Hypertension (Dallas, Tex. : 1979)|March 18, 2009
The natriuretic peptide uroguanylin elicits physiologic actions through 2 distinct topoisomersNicholas G Moss, Dorothy A Riguera, Robert M Solinga, et al.
American Journal of Physiology. Renal Physiology|September 1, 2020
Praliciguat inhibits progression of diabetic nephropathy in ZSF1 rats and suppresses inflammation and apoptosis in human renal proximal tubular cellsGuang Liu, Courtney M Shea, Juli E Jones, et al.
Pharmacology Research & Perspectives|April 22, 2020
Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical-stage soluble guanylate cyclase stimulator in ratsAli R Banijamali, Andrew E Carvalho, James D Wakefield, et al.
Diabetologia|December 21, 2019
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertensionJohn P Hanrahan, Jelena P Seferovic, James D Wakefield, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Proceedings of the National Academy of Sciences of the United States of America|February 15, 2003
Structural origins of adenine-tract bendingAndrej Barbic, Daniel P Zimmer, Donald M Crothers
FASEB Bioadvances|August 25, 2020
An impaired natriuretic peptide hormone system may play a role in COVID-19 severity in vulnerable populationsMark G Currie, Daniel P Zimmer, Perry V Halushka
Genetics|September 3, 2004
Genome image programs: visualization and interpretation of Escherichia coli microarray experimentsDaniel P Zimmer, Oleg Paliy, Brian Thomas, et al.
Handbook of Experimental Pharmacology|July 6, 2019
Correction to: Soluble Guanylate Cyclase Stimulators and ActivatorsPeter Sandner, Daniel P Zimmer, G Todd Milne, et al.
Handbook of Experimental Pharmacology|January 29, 2019
Soluble Guanylate Cyclase Stimulators and ActivatorsPeter Sandner, Daniel P Zimmer, G Todd Milne, et al.
Methods in Molecular Biology (Clifton, N.J.)|April 25, 2003
Escherichia coli spotted double-strand DNA microarrays: RNA extraction, labeling, hybridization, quality control, and data managementArkady B Khodursky, Jonathan A Bernstein, Brian J Peter, et al.
Hypertension (Dallas, Tex. : 1979)|March 18, 2009
The natriuretic peptide uroguanylin elicits physiologic actions through 2 distinct topoisomersNicholas G Moss, Dorothy A Riguera, Robert M Solinga, et al.
American Journal of Physiology. Renal Physiology|September 1, 2020
Praliciguat inhibits progression of diabetic nephropathy in ZSF1 rats and suppresses inflammation and apoptosis in human renal proximal tubular cellsGuang Liu, Courtney M Shea, Juli E Jones, et al.
Pharmacology Research & Perspectives|April 22, 2020
Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical-stage soluble guanylate cyclase stimulator in ratsAli R Banijamali, Andrew E Carvalho, James D Wakefield, et al.
Diabetologia|December 21, 2019
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertensionJohn P Hanrahan, Jelena P Seferovic, James D Wakefield, et al.
Pageof 2